Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The ob...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado: 2010
Materias:
Acceso en línea:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0021972X_v95_n11_pE373_Daly
http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly
Aporte de:
id paper:paper_0021972X_v95_n11_pE373_Daly
record_format dspace
spelling paper:paper_0021972X_v95_n11_pE373_Daly2023-06-08T14:44:49Z Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study growth hormone liothyronine octreotide somatomedin C somatostatin derivative thyrotropin thyroxine adult aip gene article cancer invasion clinical assessment controlled study dyspnea female gene mutation genetic predisposition genotype phenotype correlation germ line gigantism growth hormone blood level growth hormone secreting adenoma human human genome hypophysis adenoma hypopituitarism liothyronine blood level major clinical study male onset age priority journal prolactin release prolactinoma repeated drug dose retrospective study tachycardia thyrotropin blood level thyrotropin secreting adenoma thyroxine blood level treatment response tumor volume Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. Copyright © 2010 by The Endocrine Society. 2010 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0021972X_v95_n11_pE373_Daly http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic growth hormone
liothyronine
octreotide
somatomedin C
somatostatin derivative
thyrotropin
thyroxine
adult
aip gene
article
cancer invasion
clinical assessment
controlled study
dyspnea
female
gene mutation
genetic predisposition
genotype phenotype correlation
germ line
gigantism
growth hormone blood level
growth hormone secreting adenoma
human
human genome
hypophysis adenoma
hypopituitarism
liothyronine blood level
major clinical study
male
onset age
priority journal
prolactin release
prolactinoma
repeated drug dose
retrospective study
tachycardia
thyrotropin blood level
thyrotropin secreting adenoma
thyroxine blood level
treatment response
tumor volume
spellingShingle growth hormone
liothyronine
octreotide
somatomedin C
somatostatin derivative
thyrotropin
thyroxine
adult
aip gene
article
cancer invasion
clinical assessment
controlled study
dyspnea
female
gene mutation
genetic predisposition
genotype phenotype correlation
germ line
gigantism
growth hormone blood level
growth hormone secreting adenoma
human
human genome
hypophysis adenoma
hypopituitarism
liothyronine blood level
major clinical study
male
onset age
priority journal
prolactin release
prolactinoma
repeated drug dose
retrospective study
tachycardia
thyrotropin blood level
thyrotropin secreting adenoma
thyroxine blood level
treatment response
tumor volume
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
topic_facet growth hormone
liothyronine
octreotide
somatomedin C
somatostatin derivative
thyrotropin
thyroxine
adult
aip gene
article
cancer invasion
clinical assessment
controlled study
dyspnea
female
gene mutation
genetic predisposition
genotype phenotype correlation
germ line
gigantism
growth hormone blood level
growth hormone secreting adenoma
human
human genome
hypophysis adenoma
hypopituitarism
liothyronine blood level
major clinical study
male
onset age
priority journal
prolactin release
prolactinoma
repeated drug dose
retrospective study
tachycardia
thyrotropin blood level
thyrotropin secreting adenoma
thyroxine blood level
treatment response
tumor volume
description Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. Copyright © 2010 by The Endocrine Society.
title Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
title_short Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
title_full Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
title_fullStr Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
title_full_unstemmed Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
title_sort clinical characteristics and therapeutic responses in patients with germ-line aip mutations and pituitary adenomas: an international collaborative study
publishDate 2010
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0021972X_v95_n11_pE373_Daly
http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly
_version_ 1768545958841286656